Condition
SSc-Systemic Sclerosis
Total Trials
4
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (2)
P 1 (1)
Trial Status
Recruiting4
Clinical Trials (4)
Showing 4 of 4 trials
NCT07193810Early Phase 1Recruiting
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT07491523RecruitingPrimary
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
NCT07355972Early Phase 1RecruitingPrimary
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
NCT07315087Phase 1Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Showing all 4 trials